Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
Acute decompensated heart failure in children is characterized by high burdens of comorbidities, mortality, and frequent readmission, especially among patients with underlying congenital heart disease.
Heart transplant with or without bridge to transplant LVAD therapy was found to be associated with greater 5-year survival compared with LVAD destination therapy in patients with end-stage heart failure.
A phase 2 study of Moderna’s vaccine candidate for COVID-19, mRNA-1273, is expected to start shortly following the Food and Drug Administration’s review of the Company’s Investigational New Drug (IND) application.
The presence of obesity, type 2 diabetes, and elevated systolic blood pressure (SBP) in adolescence accelerates the progression of risk factors that play a role in the development of early vascular aging.
Oral anticoagulation with or without antiplatelet medication was found to increase the risk for bleeding, with minimal protective effect against ischemic stroke in patients with heart failure with reduced ejection fraction and sinus rhythm.